Literature DB >> 23810406

Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients.

Linong Ji1, Dayi Hu, Changyu Pan, Jianping Weng, Yong Huo, Changsheng Ma, Yiming Mu, Chuanming Hao, Qiuhe Ji, Xingwu Ran, Benli Su, Hanjing Zhuo, Keith A A Fox, Michael Weber, Danyi Zhang.   

Abstract

BACKGROUND: Individually, diabetes mellitus, hypertension, and dyslipidemia have been shown to increase the risk of cardiovascular disease. While traditional management of Type 2 diabetes has focused mainly on glycemic control, robust evidence supports the integration of hypertension and dyslipidemia management to reduce the risk of cardiovascular disease. The primary objective of this study was to assess the level of control of blood glucose, blood pressure, and blood lipids (3Bs) among patients with type 2 diabetes. An additional objective was to investigate the impact of hospital type, physician specialty, treatment pattern, and patient profile on clinical outcomes.
METHODS: This was a cross-sectional, multicenter observational study. A nationally representative sample of outpatients with established type 2 diabetes were enrolled at hospitals representative of geographic regions, tiers, and physician specialties in China. Main clinical measurements were the levels of glycosylated hemoglobin (HbA1c), blood pressure, and total serum cholesterol in reference to target goals.
RESULTS: A total of 25,817 adults with type 2 diabetes (mean age 62.6 years, 47% male) were enrolled at 104 hospitals. Seventy-two percent reported comorbid hypertension, dyslipidemia, or both. Patients with concurrent type 2 diabetes, hypertension, and dyslipidemia were 6 times more likely to report a prior history of cardiovascular disease compared with those with type 2 diabetes alone. The mean HbA1c level was 7.6%. While 47.7%, 28.4%, and 36.1% of patients achieved the individual target goals for control of blood glucose (HbA1c <7%), blood pressure (systolic blood pressure <130 mm Hg, diastolic blood pressure <80 mm Hg), and blood lipids (total cholesterol <4.5 mmol/L), respectively, only 5.6% achieved all 3 target goals. Lower body mass index (<24 kg/m(2)), no active smoking or drinking, higher education, and diabetes duration <5 years were independent predictors of better cardiovascular disease risk control.
CONCLUSION: Achieving adequate control of risk factors for cardiovascular disease in patients with type 2 diabetes remains a clinical challenge. Interventions to achieve control of 3Bs coupled with modification of additional cardiovascular disease predictors are crucial for optimization of clinical outcomes in patients with type 2 diabetes.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular risk factor; China; Dyslipidemia; Hyperglycemia; Hypertension; Type 2 diabetes

Mesh:

Substances:

Year:  2013        PMID: 23810406     DOI: 10.1016/j.amjmed.2013.02.035

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  72 in total

1.  Metabolic abnormalities in rheumatoid arthritis patients with comorbid diabetes mellitus.

Authors:  Xing Zhen Liu; Ying Gao; Jie Fan; Xia Xu; Ju Zhang; Jie Gao; Wei Wan; Dong Bao Zhao
Journal:  Clin Rheumatol       Date:  2017-09-24       Impact factor: 2.980

2.  Outline of the report on cardiovascular diseases in China, 2014.

Authors:  Chen Weiwei; Gao Runlin; Liu Lisheng; Zhu Manlu; Wang Wen; Wang Yongjun; Wu Zhaosu; Li Huijun; Zheng Zhe; Jiang Lixin; Hu Shengshou
Journal:  Eur Heart J Suppl       Date:  2016-05-24       Impact factor: 1.803

3.  Association Between Bariatric Surgery and Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity.

Authors:  David P Fisher; Eric Johnson; Sebastien Haneuse; David Arterburn; Karen J Coleman; Patrick J O'Connor; Rebecca O'Brien; Andy Bogart; Mary Kay Theis; Jane Anau; Emily B Schroeder; Stephen Sidney
Journal:  JAMA       Date:  2018-10-16       Impact factor: 56.272

4.  Research progress on prevention and treatment of glucolipid metabolic disease with integrated traditional Chinese and Western medicine.

Authors:  Jiao Guo
Journal:  Chin J Integr Med       Date:  2017-08-10       Impact factor: 1.978

5.  A nationwide assessment of blood pressure control and the associated factors in Chinese type 2 diabetes mellitus patients.

Authors:  Yu-Qing Zhang; Yong Li; Yu-Gang Dong; Yan-Hua Wu; Rui Bian; Ji-Hu Li; Li-Nong Ji
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-10-11       Impact factor: 3.738

Review 6.  THE DIABETES EPIDEMIC IN CHINA: AN INTEGRATED REVIEW OF NATIONAL SURVEYS.

Authors:  Xiuhua Shen; Anand Vaidya; Shoulin Wu; Xiang Gao
Journal:  Endocr Pract       Date:  2016-06-13       Impact factor: 3.443

7.  Achieving triple treatment goals in multi-ethnic Asian patients with type 2 diabetes mellitus in primary care.

Authors:  C C Goh; K H Koh; Scp Goh; Yle Koh; N C Tan
Journal:  Malays Fam Physician       Date:  2018-08-31

8.  Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study.

Authors:  Siyao He; Xin Qian; Yanyan Chen; Xiaoxia Shen; Bo Zhang; Xiaoping Chen; Xiangjin Xu; Guangwei Li
Journal:  J Diabetes Res       Date:  2021-06-10       Impact factor: 4.011

9.  Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus.

Authors:  Xiaoling Cai; Linong Ji
Journal:  Diabetes Ther       Date:  2021-05-28       Impact factor: 2.945

10.  The experiences of Chinese general practitioners in communicating with people with type 2 diabetes-a focus group study.

Authors:  Mi Yao; Dong-Ying Zhang; Jie-Ting Fan; Kai Lin; Shamil Haroon; Dawn Jackson; Hai Li; Wei Chen; Richard Lehman; Kar Keung Cheng
Journal:  BMC Fam Pract       Date:  2021-07-19       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.